Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abe, 2003, GATA-6 is involved in PPARgamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells, Arterioscler. Thromb. Vasc. Biol., 23, 404, 10.1161/01.ATV.0000059405.51042.A0
Aitman, 1999, Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats, Nat. Genet., 21, 76, 10.1038/5013
Artwohl, 2005, Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells, Thromb. Haemost., 93, 810, 10.1160/TH04-09-0615
Barlocco, 2005, Muraglitazar (Bristol-Myers Squibb/Merck), Curr. Opin. Investig. Drugs, 6, 427
Barroso, 1999, Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension, Nature, 402, 880, 10.1038/47254
Bishop-Bailey, 2000, Peroxisome proliferator-activated receptors in the cardiovascular system, Br. J. Pharmacol., 129, 823, 10.1038/sj.bjp.0703149
Bishop-Bailey, 1999, Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2, J. Biol. Chem., 274, 17042, 10.1074/jbc.274.24.17042
Bishop-Bailey, 2003, Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation, Prostaglandins Other Lipid Mediat., 71, 1, 10.1016/S0090-6980(03)00003-0
Blanquart, 2004, The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha, Mol. Endocrinol., 18, 1906, 10.1210/me.2003-0327
Blaschke, 2006, Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes, Arterioscler. Thromb. Vasc. Biol., 26, 28, 10.1161/01.ATV.0000191663.12164.77
Braissant, 1996, Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α,-β, and-γ in the adult rat, Endocrinology, 137, 354, 10.1210/en.137.1.354
Bruemmer, 2003, Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells, Mol. Endocrinol., 17, 1005, 10.1210/me.2002-0410
Bruemmer, 2003, Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells, Circ. Res., 93, e38, 10.1161/01.RES.0000088344.15288.E6
Bruemmer, 2005, New targets for PPARgamma in the vessel wall: implications for restenosis, Int. J. Obes. (Lond.), 29, S26, 10.1038/sj.ijo.0802910
Buse, 2005, Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes, 27, 1181
Calnek, 2003, Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells, Arterioscler. Thromb. Vasc. Biol., 23, 52, 10.1161/01.ATV.0000044461.01844.C9
Charbonnel, 2004, PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients, Diabetes Care, 27, 1647, 10.2337/diacare.27.7.1647
Chawla, 2003, PPARδ is a very low-density lipoprotein sensor in macrophages, Proc. Natl. Acad. Sci. U. S. A., 100, 1268, 10.1073/pnas.0337331100
Cheng, 2004, Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes, Biochem. Biophys. Res. Commun., 313, 277, 10.1016/j.bbrc.2003.11.127
Chinetti, 1998, Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages, J. Biol. Chem., 273, 25573, 10.1074/jbc.273.40.25573
Chinetti, 2003, Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications, Int. J. Obes. Relat. Metab. Disord., 27, S41, 10.1038/sj.ijo.0802499
Delerive, 1999, Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1, J. Biol. Chem., 274, 32048, 10.1074/jbc.274.45.32048
Delerive, 2001, Peroxisome proliferator-activated receptors in inflammation control, J. Endocrinol., 169, 453, 10.1677/joe.0.1690453
1999, Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway, Circ. Res., 85, 394, 10.1161/01.RES.85.5.394
Desvergne, 1999, Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr. Rev., 20, 649, 10.1210/er.20.5.649
de Dios, 2003, Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-γ Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation, Circulation, 107, 2548, 10.1161/01.CIR.0000074040.31731.96
Diep, 2001, Increased expression of peroxisome proliferator-activated receptor-α and-γ in blood vessels of spontaneously hypertensive rats, Hypertension, 38, 249, 10.1161/01.HYP.38.2.249
Diep, 2000, Endothelin-1 attenuates ω-3 fatty acid-induced apoptosis by inhibition of caspase 3, Hypertension, 3, 287, 10.1161/01.HYP.35.1.287
Diep, 2000, Docosahexaenoic acid, a peroxisome proliferator-activated receptor-α activator, induces apoptosis in vascular smooth muscle cells by activation of p38 mitogen-activated protein kinase, Hypertension, 36, 851, 10.1161/01.HYP.36.5.851
Diep, 2002, PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation, Hypertension, 40, 866, 10.1161/01.HYP.0000037969.41360.CC
Diep, 2002, Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ, Circulation, 105, 2296, 10.1161/01.CIR.0000016049.86468.23
Diep, 2004, PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats, J. Mol. Cell. Cardiol., 36, 295, 10.1016/j.yjmcc.2003.11.004
Diradourian, 2005, Phosphorylation of PPARs: from molecular characterization to physiological relevance, Biochimie, 87, 33, 10.1016/j.biochi.2004.11.010
2001, Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study, Lancet, 357, 905, 10.1016/S0140-6736(00)04209-4
Ericsson, 1997, Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]), Am. J. Cardiol., 80, 1125, 10.1016/S0002-9149(97)00626-7
Evans, 2000, Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus, Circulation, 101, 1773, 10.1161/01.CIR.101.15.1773
Flavell, 2002, Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease, Circulation, 105, 1440, 10.1161/01.CIR.0000012145.80593.25
Frick, 1987, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N. Engl. J. Med., 317, 1237, 10.1056/NEJM198711123172001
Frick, 1997, Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group, Circulation, 96, 2137, 10.1161/01.CIR.96.7.2137
Goya, 2004, Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells, Arterioscler. Thromb. Vasc. Biol., 24, 658, 10.1161/01.ATV.0000118682.58708.78
Graham, 2005, The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice, Atherosclerosis, 182, 381, 10.1016/j.atherosclerosis.2005.05.014
Haffner, 2002, Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus, Circulation, 106, 679, 10.1161/01.CIR.0000025403.20953.23
Han, 2005, Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators, Hypertension, 46, 1086, 10.1161/01.HYP.0000187900.36455.4c
Hannan, 2003, Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta, Arterioscler. Thromb. Vasc. Biol., 1; 23, 762, 10.1161/01.ATV.0000069210.46539.0D
Hansen, 2001, Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling, J. Biol. Chem., 276, 3175, 10.1074/jbc.M005567200
Harrity, 2006, Muraglitazar, a Novel Dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves {beta}-Cell Function in db/db Mice, 55, 240
Hennuyer, 1999, Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response, Circulation, 99, 2445, 10.1161/01.CIR.99.18.2445
Horio, 2005, Pioglitazone improves left ventricular diastolic function in patients with essential hypertension, Am. J. Hypertens., 18, 949, 10.1016/j.amjhyper.2005.02.003
Iglarz, 2003, Effect of peroxisome proliferator-activated receptor-α and-γ activators on vascular remodeling in endothelin-dependent hypertension, Arterioscler. Thromb. Vasc. Biol., 23, 45, 10.1161/01.ATV.0000047447.67827.CD
Inoue, 1998, Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells, Biochem. Biophys. Res. Commun., 246, 370, 10.1006/bbrc.1998.8622
Irukayama-Tomobe, 2004, Activation of Peroxisome Proliferator-activated Receptor-alpha Decreases Endothelin-1-induced p38 Mitogen-activated Protein Kinase Activation in Cardiomyocytes, J. Cardiovasc. Pharmacol., 44, S358, 10.1097/01.fjc.0000166303.33313.01
Ishibashi, 2002, Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone, Hypertension, 40, 687, 10.1161/01.HYP.0000036396.64769.C2
Israelian-Konaraki, 2005, Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications, Cardiol. Rev., 13, 240, 10.1097/01.crd.0000137255.54390.12
Issemann, 1991, Cloning of novel members of the steroid hormone receptor superfamily, J. Steroid Biochem. Mol. Biol., 40, 263, 10.1016/0960-0760(91)90191-7
James, 2005, Brophy, Selling Safety-Lessons From Muraglitazar, JAMA, 294, 2633, 10.1001/jama.294.20.jed50074
Jiang, 1998, PPAR-γ agonists inhibit production of monocyte inflammatory cytokines, Nature, 391, 82, 10.1038/35154
Kliewer, 1994, Differential expression and activation of a family of murine peroxisome proliferator-activated receptors, Proc. Natl. Acad. Sci. U. S. A., 91, 7355, 10.1073/pnas.91.15.7355
Law, 2001, PPARγ and atherosclerosis: effects on cell growth and movement, Arterioscler. Thromb. Vasc. Biol., 21, 1891, 10.1161/hq1201.100261
Law, 1996, Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia, J. Clin. Invest., 98, 1897, 10.1172/JCI118991
Law, 2000, Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells, Circulation, 101, 1311, 10.1161/01.CIR.101.11.1311
Lee, 2000, Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells, Circ. Res., 87, 516, 10.1161/01.RES.87.6.516
Lee, 2003, Transcriptional repression of atherogenic inflammation: modulation by PPARdelta, Science, 302, 453, 10.1126/science.1087344
Lee, 2003, Transcriptional repression of atherogenic inflammation: modulation by PPARdelta, Science, 302, 453, 10.1126/science.1087344
Leibowitz, 2000, Activation of PPARdelta alters lipid metabolism in db/db mice, FEBS Lett., 473, 333, 10.1016/S0014-5793(00)01554-4
Li, 2000, Peroxisome proliferators activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice, J. Clin. Invest., 106, 523, 10.1172/JCI10370
Madej, 1998, Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb, Int. J. Clin. Pharmacol. Ther., 36, 345
Marx, 1999, PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells, Circulation, 99, 3125, 10.1161/01.CIR.99.24.3125
Marx, 2000, Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells, J. Immunol., 164, 6503, 10.4049/jimmunol.164.12.6503
Marx, 2003, Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease, Circulation, 107, 1954, 10.1161/01.CIR.0000069272.06194.91
Marx, 2004, Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells, Circ. Res., 94, 1168, 10.1161/01.RES.0000127122.22685.0A
Muscat, 2005, Cardiovascular disease and PPARdelta: targeting the risk factors, Curr. Opin. Investig. Drugs, 6, 887
Nissen, 2005, Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus, 294, 2581
Olefsky, 2000, PPAR gamma and the treatment of insulin resistance, Trends Endocrinol. Metab., 11, 362, 10.1016/S1043-2760(00)00306-4
Oliver, 2001, A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport, Proc. Natl. Acad. Sci. U. S. A., 98, 5306, 10.1073/pnas.091021198
Patel, 2005, Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?, Diab. Vasc. Dis. Res., 2, 61, 10.3132/dvdr.2005.010
Planavila, 2005, Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes, Cardiovasc. Res., 65, 832, 10.1016/j.cardiores.2004.11.011
Playford, 2002, Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus, Am. J. Cardiol., 90, 1254, 10.1016/S0002-9149(02)02847-3
Rhee, 2006, Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome, Arch. Med. Res., 37, 86, 10.1016/j.arcmed.2005.04.008
Ricote, 1999, The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function, J. Leukoc. Biol., 66, 733, 10.1002/jlb.66.5.733
Ricote, 2004, Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 24, 230, 10.1161/01.ATV.0000103951.67680.B1
Robins, 2003, Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT), Diabetes Care, 26, 1513, 10.2337/diacare.26.5.1513
Saltiel, 1996, Thiazolidinediones in the treatment of insulin resistance and type II diabetes, Diabetes, 45, 1661, 10.2337/diabetes.45.12.1661
Sarafidis, 2005, The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension: An open-label observational study, Metabolism, 54, 1236, 10.1016/j.metabol.2005.04.010
Sarafidis, 2005, The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension, Am. J. Hypertens., 18, 227, 10.1016/j.amjhyper.2004.09.010
Satoh, 2003, Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect, Diabetes Care, 26, 2493, 10.2337/diacare.26.9.2493
Schiffrin, 2005, Peroxisome proliferator-activated receptors and cardiovascular remodeling, Am. J. Physiol, Heart Circ. Physiol., 288, H1037, 10.1152/ajpheart.00677.2004
Sidhu, 2003, The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients, J. Am. Coll. Cardiol., 42, 1757, 10.1016/j.jacc.2003.04.001
Sidhu, 2004, Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease Patients without diabetes mellitus, Arterioscler. Thromb. Vasc. Biol., 24, 930, 10.1161/01.ATV.0000124890.40436.77
Staels, 1998, Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators, Nature, 393, 790, 10.1038/31701
Takagi, 2000, Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study, J. Am. Coll. Cardiol., 36, 1529, 10.1016/S0735-1097(00)00895-0
Tan, 2001, Critical roles of PPAR beta/delta in keratinocyte response to inflammation, Genes Dev., 15, 3263, 10.1101/gad.207501
Tao, 2003, Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia, Circulation, 108, 2805, 10.1161/01.CIR.0000097003.49585.5E
Tontonoz, 1994, Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor, Cell, 79, 1147, 10.1016/0092-8674(94)90006-X
Varo, 2003, Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones, Circulation, 107, 2664, 10.1161/01.CIR.0000074043.46437.44
Vosper, 2001, The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages, J. Biol. Chem., 276, 44258, 10.1074/jbc.M108482200
Wakino, 2001, Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells, J. Biol. Chem., 276, 47650, 10.1074/jbc.M108719200
Wang, 2003, Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity, Cell, 113, 159, 10.1016/S0092-8674(03)00269-1
Wang, 2004, Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage— A new paradigm in glitazone pleiotropy, Circulation, 109, 1392, 10.1161/01.CIR.0000123231.49594.21
Wang, 2004, Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome, Am. J. Cardiol., 93, 362, 10.1016/j.amjcard.2003.10.022
Zhang, 2002, 15-Deoxy-prostaglandin J(2) inhibits PDGF-A and-B chain expression in human vascular endothelial cells independent of PPAR gamma, Biochem. Biophys. Res. Commun., 298, 128, 10.1016/S0006-291X(02)02401-4
Zhang, 2002, Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells, J. Biol. Chem., 277, 11505, 10.1074/jbc.M110580200